Provided by Tiger Fintech (Singapore) Pte. Ltd.

Fractyl Health

1.28
+0.07506.22%
Post-market: 1.28-0.0001-0.01%19:25 EDT
Volume:214.41K
Turnover:275.39K
Market Cap:62.62M
PE:-0.79
High:1.32
Open:1.24
Low:1.21
Close:1.21
Loading ...

Company Profile

Company Name:
Fractyl Health
Exchange:
NASDAQ
Establishment Date:
2010
Employees:
107
Office Location:
3 Van de Graaff Drive,Suite 200,Burlington,Massachusetts,United States
Zip Code:
01803
Fax:
- -
Introduction:
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.

Directors

Name
Position
Allan R. Will
Chairman
Harith Rajagopalan
Co-Founder, Chief Executive Officer, Director
Ajay Royan
Director
Amy W. Schulman
Director
Clive Meanwell
Director
Kelly Barnes
Director
Marc Elia
Director
Samuel Conaway
Director
William W. Bradley
Director

Shareholders

Name
Position
Harith Rajagopalan
Co-Founder, Chief Executive Officer, Director
Lisa A. Davidson
Chief Financial Officer, Treasurer
Jay D. Caplan
Co-Founder, President, Chief Product Officer
Sarah Toomey
General Counsel, Corporate Secretary
Timothy Kieffer
Chief Scientific Officer